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A B S T R A C T
Background: Evidence for guideline recommendations for the treatment of venous thromboembolism (VTE)
during anticoagulant therapy is scarce. We aimed to observe and to describe the management of VTE occurring
during anticoagulant therapy.
Methods: This prospective multi-center, observational study included patients with objectively confirmed VTE
during anticoagulant therapy (breakthrough event), with a follow-up of 3 months, after the breakthrough event.
Results: We registered 121 patients with a breakthrough event, with a mean age of 56 years (range, 19 to 90); 61
were male (50%). Fifty-eight patients (48%) had an active malignancy. At the time of the breakthrough event, 57
patients (47%) were treated with a vitamin K antagonist (VKA), 53 patients (44%) with low-molecular-weight
heparin (LMWH) and 11 patients (9%) with direct oral anticoagulants, unfractionated heparin, or VKA plus
LMWH. A total of 21 patients (17%) were receiving a subtherapeutic dose of an anticoagulant. The main re-
gimens to treat recurrence in patients on VKA were: switch to LMWH (33%), temporary double treatment with
LMWH and VKA (23%), and VKA with a higher target INR (19%). In patients with a breakthrough on LMWH, the
most frequently chosen regimen was a permanent dose increase (74%). During 3-month follow-up, 7% of pa-
tients had a second breakthrough event and 8% experienced major or clinically relevant non-major bleeding.
Conclusion: There is wide variation in the management of VTE during anticoagulant treatment, reflecting a
heterogeneous and complex clinical situation. Despite intensifying anticoagulation, the risk of a second break-
through event in this population is 7%.
1. Introduction
Ever since the landmark trial by Barritt and Jordan in 1960, it is
clear that patients with venous thromboembolism (VTE) benefit from
anticoagulant treatment [1]. Currently available long-term treatment
options include direct oral anticoagulants (DOACs), vitamin K antago-
nists (VKAs), and subcutaneous low-molecular-weight heparin (LMWH)
[2]. Anticoagulants are very effective and reduce the risk of recurrent
VTE by 90–97%. During the first 3–6 months of treatment, the risk of
recurrent VTE is about 0,4–2% whereas after treatment the risk of
recurrence is 10% in the first year and 36% after 10 years, with a fatal
recurrent risk of 4% [3,4]. The risk of recurrent VTE during antic-
oagulant therapy is particularly high in patients with persistent major
provoking factors, such as active cancer or antiphospholipid syndrome
[5–7]. During the initial 6 months of treatment, cancer patients have a
7% to 8% risk of developing recurrent VTE despite treatment [8–10].
The management of VTE in cancer patients is further complicated by a
3-fold increased risk of anticoagulant-associated major bleeding
[6,7,11]. LMWH is the recommended treatment option for cancer-as-
sociated VTE because of superior efficacy to VKA while carrying a
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similar risk of bleeding [8,9,12]. However, recently a randomized
controlled trial showed that edoxaban was non-inferior to dalteparin in
prevention of cancer related VTE, with a higher risk of major bleeding,
mainly gastrointestinal [13]. Likewise, a pilot study comparing rivar-
oxaban to dalteparin showed similar efficacy and safety [14].
Little is known about the clinical course and optimal therapeutic
management of VTE in patients who are already receiving antic-
oagulant therapy. In contrast to the firm evidence- based treatment of a
first VTE, no randomized trials have addressed the management of VTE
in already anticoagulated patients. Based on low-quality evidence, the
guideline by the American College of Chest Physicians (ACCP) suggests
switching treatment to LMWH when VTE occurs during VKA [2,15]. If
VTE occurs during LMWH therapy, a dose increase by 25% to 33% is
suggested [2,15].
The aim of this prospective cohort study was to evaluate the man-
agement of VTE in anticoagulated patients in clinical practice, and to
assess the 3-month incidence of recurrent VTE and bleeding.
2. Methods
This was a multicenter, prospective, observational study, conducted
between September 2010 and December 2015 in 10 Dutch academic
and non-academic hospitals. All patients with objectively confirmed
VTE and current anticoagulant treatment for any indication (e.g. atrial
fibrillation, prior VTE, or mechanical heart valve) were eligible.
Qualifying index events, i.e. breakthrough events, for inclusion in this
study were distal or proximal deep vein thrombosis (DVT) of the leg,
acute pulmonary embolism (PE), upper extremity DVT, or splanchnic
vein thrombosis. DVT was defined as non-compressibility of a previous
compressible venous segment or an increase of at least 4 mm of the
diameter of the residual thrombus. PE was defined as a new thrombus
on computerized tomography pulmonary angiography, new mis-
matched defect on a ventilation/perfusion lung scan, or new defect on a
pulmonary angiogram. Splanchnic vein thrombosis was defined as ve-
nous obstruction or absence of flow objectified by ultrasonography,
duplex Doppler ultrasound, computerized tomography, or magnetic
resonance imaging. Patient with a life expectancy of< 3 months,
pregnant women, and patients requiring thrombolytic therapy for their
breakthrough VTE were excluded.
Because of the absence of solid data on the risk of a breakthrough
VTE during anticoagulant treatment when the study was planned, we
did not perform a formal sample size calculation and targeted a sample
size of 100 participants.
At baseline, information was collected on provoking factors, loca-
tion of VTE, anticoagulant treatment at the time of the breakthrough
event, and management of the breakthrough event. Anti-factor Xa le-
vels in LMWH recipients and INR in patients treated with VKA were not
routinely collected. Active cancer was defined as a cancer diagnosis or
treatment within the past 6 months, or recurrent, locally advanced, or
metastatic disease. For patients with active cancer, additional in-
formation was collected about the type of cancer, presence of distant
metastases, and cancer treatment in the last 3 months. All patients were
contacted after 3 months after the breakthrough event through tele-
phone or visit. Standardized questions were used, in order to capture
data on a second breakthrough event during treatment, anticoagulant-
related bleeding, and death.
Anticoagulant regimens at time of the breakthrough event were
classified as subtherapeutic, therapeutic, or supratherapeutic.
Therapeutic LMWH was defined as within± 20% of the recommended
weight-based dose in patients without renal impairment, i.e. for dal-
teparin 160–240 IU/kg/24 h, for tinzaparin 140–210 IU/kg/24 h, for
nadroparin 69–103 IU/kg/12 h (twice daily dosing), nadroparin
137–205 IU/kg/24 h (once daily dosing), for enoxaparin 0.8–1.2 mg/
kg/12 h (twice daily dosing), enoxaparin 1.2–1.8 mg/kg/24 h (once
daily dosing). Therapeutic VKA was defined as an INR between 2.0 and
3.5. For patients using a DOAC, rivaroxaban 20 mg once daily, apixaban
5 mg twice daily, edoxaban 60 mg once daily or 30 mg once daily in
those qualifying for dose reduction, and dabigatran 150 mg twice daily
or 110 mg twice daily in those qualifying for dose reduction were
classified as ‘therapeutic’. Doses below or above these ranges were
classified as ‘subtherapeutic’ and ‘supratherapeutic’, respectively. Any
case of a combination of two different types of anticoagulants was
considered as ‘supratherapeutic’.
As this was an observational study, patients were treated at the
discretion of treating physicians and not by a standardized treatment
protocol. Data and motivation on the (change of) management of the
breakthrough thrombotic event were collected on a predefined form,
including type and dose of anticoagulant, type of inferior caval vein
filter or other mechanical/medical treatment options. Given the ob-
servational design, the Medical Ethical Committee of the Amsterdam
UMC waived the need for informed consent.
2.1. Primary efficacy and safety outcomes
The primary efficacy outcome was an objectively confirmed,
(second) recurrent VTE during three-month follow-up. Patients were
contacted at the end of the three-month follow-up period and also in
case of an event (either recurrent VTE or bleeding) during this follow-
up period. During the follow-up visit or telephone contact, detailed
information was collected about an eventually recurrent VTE, such as
date and location of the thrombosis and whether this VTE was objec-
tively confirmed, and if so, by which imaging modality. Also, detailed
information on any bleeding was collected, such as date, location and
severity. Furthermore, if applicable, information on a newly diagnosed
malignancy was gathered, including tumor (histological) type, location,
(TNM) stage. Lastly, in case of death, the cause was collected, parti-
cularly whether the death was related to pulmonary embolism, to other
cardiovascular causes such as myocardial infarction or stroke, or to
major bleeding.
Recurrent DVT was defined as non-compressibility of a previous
compressible venous segment or an increase of at least 4 mm of the
diameter of the residual thrombus. Recurrent PE was defined as a new
thrombus on computerized tomography pulmonary angiography, new
mismatched defect on a ventilation/perfusion lung scan or new defect
on a pulmonary angiogram. Splanchnic vein thrombosis was defined as
venous obstruction or absence of flow objectified by ultrasonography,
duplex Doppler ultrasound, computerized tomography or magnetic re-
sonance imaging.
The primary safety outcome was the composite of major or clini-
cally relevant non-major bleeding according to the ISTH criteria [15].
Major bleeding was defined as clinically overt bleeding that either (1)
was associated with a drop in hemoglobin level of 1.24 mmol/L (2 g/
dL) or more, (2) led to transfusion of 2 or more units of whole blood or
red cells, (3) was located in a critical area or organ, such as intraspinal,
intracranial, intraocular, intra-articular, retroperitoneal, or pericardial,
or intramuscular with compartment syndrome, or (4) fatal bleeding
[15]. Clinically relevant non-major bleeding was defined as any sign or
symptom of hemorrhage (e.g., more bleeding than would be expected
for a clinical circumstance, including bleeding found by imaging alone)
that did not meet the criteria for the definition of major bleeding but
did meet at least one of the following criteria: (1) requiring medical
intervention by a healthcare professional, (2) leading to hospitalization
or increased level of care, or (3) prompting a face to face (i.e., not just a
telephone or electronic communication) evaluation [16,17]. All out-
come events were adjudicated by two experienced clinicians (M.C. and
S.M.), who were blinded to the management of the breakthrough event.
Death was considered to be due to PE if this diagnosis was docu-
mented at autopsy, if the patient died shortly after objectively con-
firmed symptomatic PE in the absence of any alternative diagnosis, or
patient died suddenly and PE could not be ruled out.
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2.2. Statistical analyses
Descriptive statistics were used for demographics and clinical
characteristics of patients with different treatments. Kaplan-Meier sur-
vival analysis was performed to graphically illustrate the cumulative
incidence of a second breakthrough event and the composite of major
and clinically relevant non-major bleeding. The cumulative incidence of
recurrent VTE and bleeding were compared between cancer patients
and patients without cancer using the log-rank test with the significance
level at 0.05. All statistical analyses were performed in R, version 3.2.2
(R Foundation for Statistical Computing, Vienna, Austria, www.R-
project.org).
3. Results
A total of 121 patients were diagnosed with a (symptomatic)
breakthrough event during anticoagulant treatment, in one of the par-
ticipating centers and therefore included in this observational study.
The median age of the study group was 56 years (range, 19 to 90) and
50% were male. The indication for anticoagulation prior to the break-
through event was previous VTE in 103 patients (85%), atrial fibrilla-
tion (AF) in 9 patients (7%), and both in 3 patients (3%). Other baseline
characteristics are presented in Table 1. Thirteen patients included in
the present study were also included in an international registry on
recurrent VTE in cancer patients [16]. Five patients were lost to follow-
up during the 3-month follow-up.
3.1. Breakthrough event characteristics
The breakthrough event was a lower extremity DVT in 60 patients
(50%) and PE with or without DVT in 41 patients (34%); the remaining
16% of patients had other types of VTE (Table 1).
A major provoking factor was present at the time of breakthrough
event in 86 patients (71%): 58 patients had active cancer and 8 patients
had antiphospholipid syndrome. Thirty-five patients had an un-
provoked breakthrough VTE (Table 1). Sixty-nine percent of malig-
nancies were solid cancers, with the most prevalent tumor types being
breast (10%), pancreatic (10%), lung (9%), and gynaecological (9%)
cancer (Table 2). Distant metastases were present in 22 patients (38%);
39 patients (67%) were receiving cancer therapy (Table 2).
Anticoagulant treatment at the time of the breakthrough event was
VKA therapy in 57 patients (47%), LMWH in 53 patients (44%), VKA
plus LMWH in 4 patients (3%), and rivaroxaban, dabigatran, edoxaban,
or unfractionated heparin in 7 patients (7%, Table 1). In patients with
cancer, the majority (N = 40, 69%) was receiving LMWH, whereas
patients without cancer were predominantly receiving VKA (N = 42,
67%, Table 3). In cancer patients, 49 patients (84%) were receiving
therapeutic or supratherapeutic treatment, which was the case in 46
patients (73%) without cancer (Table 3). Twenty-two patients had an
unprovoked breakthrough event while receiving therapeutic or su-
pratherapeutic anticoagulant therapy.
3.2. Management of breakthrough event
In VKA treated patients, management consisted of a switch to
LMWH in 33%, temporary addition of LMWH in 23%, and increase of
target INR to 3.0 to 4.0 in 19% (Table 4). Among the patients receiving
LMWH at the time of the breakthrough event, treating physicians most
frequently increased the LMWH dose (74%, Table 4).
The management regimen resulted in intensified treatment for 79
patients (65%) (Table 5a). In 25 patients (21%), the treatment was not
intensified and kept at a subtherapeutic, therapeutic, or suprather-
apeutic dose (Table 5a). In 4 patients (3%) the treatment intensity was
decreased from supratherapeutic to therapeutic with a switch from VKA
to LMWH in 2 patients, switch from DOAC to VKA in one patient, and
switch from LMWH to argatroban due to heparin-induced
Table 1
Baseline characteristics.
Characteristic N = 121
Age, years, median (range) 56 (19–90)
Male, n (%) 60 (50)
Body mass index, kg/m2, mean (SD) 27 (6)
Creatinine clearance, mL/min, median (IQR) 96 (73–121)
Indication for anticoagulation, n (%)
- Venous thromboembolism 103 (85)
- Atrial fibrillation 9 (7)
- Venous thromboembolism and atrial fibrillation 3 (3)
- Other 2 (2)
- Unknown 4 (3)
Type of VTE, n (%)
- Lower extremity deep vein thrombosis
Distal
Proximal
60 (50)
6 (5)
54 (45)
- Pulmonary embolism±deep vein thrombosis 41 (34)
- Upper extremity deep vein thrombosis 11 (9)
- Inferior caval vein thrombosis 3 (2)
- Splanchnic vein thrombosis 3 (2)
- Other 3 (2)
Provoking factors, n (%)
- None 35 (29)
- Active cancera 58 (48)
- Antiphospholipid syndrome 8 (7)
- Immobilization 9 (7)
- Oral contraceptives 4 (3)
- Central venous catheter 8 (7)
- Long-haul flight ≥8 h 1 (1)
- Otherb 9 (7)
- Unknown 4 (3)
Anticoagulant treatment at time of breakthrough, n (%)
- Vitamin K antagonists 57 (47)
- Low-molecular-weight heparin 53 (44)
- Vitamin K antagonist and low-molecular-weight heparin 4 (3)
- Rivaroxaban 3 (3)
- Dabigatran 2 (2)
- Unfractionated heparin 1 (1)
- Concomitant antiplatelet agents, n (%) 8 (7)
IQR: interquartile range; PICC: peripherally inserted central catheter; SD:
standard deviation; VTE: Venous thromboembolism.
a Cancer diagnosis or any anticancer treatment in the past 6 months, or re-
current or metastatic cancer.
b Other risk factors as reported by the treating physician: one case of VTE
due to extensive retroperitoneal fibrosis with compression of the veins, one
post-kidney transplantation, one after PICC catheter removal, one during
pregnancy, one during chemotherapy, one case of thrombus in the right atrium
due to implantable cardioverter defibrillator wire in situ, one patient had focal
liver cirrhosis as risk factor and in 3 patients a risk factor was reported present,
without further specification.
Table 2
Baseline characteristics of 58 cancer patients.
Characteristic n, (%)
Solid cancer 40 (69)
- Breast 6 (10)
- Pancreas 6 (10)
- Lung 5 (9)
- Gynaecological 5 (9)
- Colorectal 4 (7)
- Esophagus 3 (5)
- Kidney 2 (3)
- Prostate 2 (3)
- Other 7 (12)
Distant metastasis 22 (38)
Hematological 16 (28)
- Polycythemia vera or essential thrombocytosis 5 (9)
- Leukemia 4 (7)
- Lymphoma 4 (7)
- Multiple myeloma 3 (5)
Unknown 2 (3)
Cancer therapy in the past 3 months 39 (67)
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thrombocytopenia in one patient.
Data on the anticoagulant intensity at time of the breakthrough
event were missing for 6 patients and on the management at time of the
breakthrough event for 7 patients, (Tables 5a and 5b).
3.3. Recurrent VTE, bleeding and death during 3 months follow-up
During 3-month follow-up, 6 patients (5%) developed recurrent
VTE, of whom 4 had active cancer (Fig. 1). Five of the 6 events occurred
in patients in whom anticoagulant treatment was intensified from
subtherapeutic to therapeutic (N = 2) or from therapeutic to su-
pratherapeutic (N = 3). In the remaining patient, the supratherapeutic
treatment regimen was not changed after the breakthrough event.
During follow-up, 12 patients out of 121 (10%) died, often due to
cancer progression (10/12). Fatal PE, including sudden death in which
PE could not be ruled out, occurred in 2 out of 12 patients. In a worst-
case scenario assuming these two patients had fatal PE, the case fatality
risk would be 17% (95% CI 5–45%). Including the latter patients in
whom PE could not be ruled out (n = 2), the 3-month risk of a second
breakthrough event (n = 8) was 6.6% (95% CI 3.4–13%).
The composite of major or clinically relevant non-major bleeding
occurred in 10 patients (8%), of whom 7 had cancer (Fig. 2). Five of
these 10 bleeding events were adjudicated as major bleeding. Bleeding
occurred during supratherapeutic and therapeutic anticoagulant treat-
ment in 8 and 2 patients, respectively. Seven of the bleeding events
occurred in patients with intensified anticoagulant treatment, 2
bleeding events occurred in patients who had remained on the same
treatment intensity and 1 bleeding occurred in a patient who was on
therapeutic anticoagulant (the treatment intensity at time of break-
through was unknown; Tables 5a and 5b).
4. Discussion
This observational study provides clinical information on the man-
agement and outcome of breakthrough VTE events during antic-
oagulant treatment in a broad spectrum of patients. Many different
treatment approaches in a heterogeneous population were observed,
which illustrates the complexity of this clinical problem and conse-
quently the challenge for one straightforward guideline. Also, large
studies or guidelines on the diagnostic-work-up of recurrent VTE,
especially during anticoagulant therapy, are lacking.
Breakthrough events are uncommon; and if VTE develops despite
anticoagulation, it can often be ascribed to underlying patient-related
or treatment-related factors [4,18]. Most of the breakthrough events
occurred in patients with an intrinsic persistent thrombotic tendency,
such as those with active cancer or antiphospholipid syndrome. Treat-
ment-related causes for a breakthrough event could include sub-
therapeutic anticoagulation due to drug-drug or drug-food interactions,
prescription errors, and non-compliance.
Whereas the majority of patients without cancer received VKA
treatment at baseline, most of the cancer patients were treated with
LMWH, which was in accordance with international guidelines, at the
time of inclusion [2]. Cancer patients with a breakthrough event during
LMWH were managed with a dose increase in> 80% of cases, which is
the suggested treatment in this population [2,18]. Despite increasing
the treatment intensity, the risk of a second breakthrough event was
higher in cancer patients (9%), while bleeding rates were also higher
(12%). This illustrates the challenges in the management of VTE in a
population that has an intrinsic thrombotic as well as bleeding ten-
dency. The risks of a second breakthrough event and major bleeding in
cancer patients observed in the present study were lower as compared
to previous studies [4,18–20]. For example Schulman and colleagues
found a second breakthrough in 11% of the 212 observed patients with
cancer, with a major bleeding risk of 8% and 27% died in 3 months
follow-up. This might be due to differences in study population, such as
lower percentage of cancer patients and within our cancer population
were fewer with metastatic disease (38% versus 55–73%) and a rela-
tively high proportion of patients with hematological cancer (28%)
[8,9,11,18].
Although most breakthrough events were managed by intensified
anticoagulant treatment, still 24% of patients were continued on the
Table 3
Treatment intensity at time of breakthrough event.
VKA treatment, N = 57 No cancer,
N = 42 (%)
Cancer,
N = 15 (%)
Total
N = 57 (%)
VKA, INR < 2.0 11 (26) 4 (27) 15 (26)
VKA, INR 2.0–3.5 25 (60) 9 (60) 34 (60)
VKA, INR > 3.5 4 (9) 2 (13) 6 (11)
VKA, INR unknown 2 (5) 0 (0) 2 (4)
LMWH, N = 53 No cancer,
N = 13 (%)
Cancer,
N = 40 (%)
Total
N = 53 (%)
LMWH, sub-therapeutic 2 (15) 3 (8) 5 (9)
LMWH, therapeutic 8 (62) 30 (75) 38 (72)
LMWH, supra-therapeutic 2 (15) 5 (12) 7 (13)
LMWH, unknown 1 (8) 2 (5) 3 (6)
Other, N = 11 No cancer,
N = 8 (%)
Cancer,
N = 3 (%)
Total
N = 11 (%)
VKA and LMWH 2 (25) 2 (67) 4 (36)
Rivaroxaban 20 mg od 1 (13) 1 (33) 2 (18)
Rivaroxaban 15 mg bid 1 (13) 0 (0) 1 (9)
Dabigatran 150 mg bid 2 (25) 0 (0) 2 (18)
Edoxaban 60 mg od 1 (13) 0 (0) 1 (9)
UFH, sub-therapeutic dose 1 (13) 0 (0) 1 (9)
INR: international normalised ratio; LMWH: low-molecular-weight heparin;
UFH: unfractionated heparin; VKA: vitamin K antagonists;
Table 4
Changes in anticoagulant therapy to treat breakthrough event.
VKA at breakthrough N = 57 No cancer,
N = 40 (%)
Cancer,
N = 14 (%)
Total
N = 57 (%)
VKA switched to LMWH 11 (27) 8 (57) 19 (33)
VKA switched to DOAC 3 (8) 0 (0) 3 (5)
VKA at therapeutic INR 1 (3) 1 (7) 2 (4)
VKA increased to supra-therapeutic
INR
10 (25) 1 (7) 11 (19)
LMWH added to VKA temporarily 10 (25) 3 (22) 13 (23)
LMWH added to VKA permanently 5 (12) 1 (7) 6 (11)
Unknown, N = 3 3 (5)
LMWH at breakthrough N = 53 No cancer,
N = 12 (%)
Cancer,
N = 40 (%)
Total
N = 53 (%)
LMWH permanent dose increase 6 (50) 33 (83) 39 (74)
LMWH same dose continued 2 (17) 5 (12) 7 (13)
LMWH switch to VKA at supra-
therapeutic INR
1 (8) 0 (0) 1 (2)
VKA added to LMWH 3 (25) 2 (5) 5 (9)
Unknown, N = 1 1 (2)
DOAC at breakthrough N = 3 No cancer,
N = 2 (%)
Cancer,
N = 1 (%)
Total
N = 3 (%)
DOAC switched to VKA 1 (50) 0 (0) 1 (33)
DOAC switched to LMWH 1 (50) 1 (100) 2 (67)
Other N = 12 No cancer,
N = 9
Cancer,
N = 3
DOAC: direct oral anticoagulants; INR: international normalised ratio; LMWH:
low-molecular-weight heparin; UFH: unfractionated heparin; VKA: vitamin K
antagonists.
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same or a decreased dose, whereas Schulman et al. found a percentage
of 33% with an unchanged therapeutic dose of anticoagulation (73%
had LMWH) [18]. The specific considerations for these clinical deci-
sions may include perceived non-compliance or a very high risk of
bleeding as judged by the treating physician.
This study in both cancer and non-cancer patients providing data on
the treatment strategies and outcomes after breakthrough VTE can help
in the design of future management studies on breakthrough events.
Strengths include the prospective data collection, multicenter design,
and adjudication of outcome events by two experts who were blinded
for treatment information. Some aspects of this study merit considera-
tion. The observational aspect of the study gave the treating physician
only some treating suggestions, without randomisation between the
various treatment options. Since the choice for a specific approach is
strongly correlated with patient- and physician-related factors, we were
not able to draw conclusions about the risk of a breakthrough during
follow-up or bleeding associated with these approaches in this popu-
lation. In addition, anti-factor Xa levels in LMWH recipients and INR in
patients treated with VKA were not routinely available, hampering the
interpretation of management decisions. Furthermore, a therapeutic
INR at the moment of a breakthrough does not reflect a consistent,
stable therapeutic range in the weeks before presentation. Most patients
used LMWH or VKA, however nowadays an increasing number of pa-
tients, also those with cancer, receive direct oral anticoagulants.
Also, patients did not undergo standardized imaging, including ul-
trasound of the legs and a chest CT-scan, at baseline and follow-up; in
some cases it is therefore hard to conclude that patients have an actual
“breakthrough” event. Two out of the ten participating centers, were
academic hospitals, specializing in hematologic cancers, resulting in a
relatively high proportion of hematologic patients, and possibly also in
a higher proportion of patients with VTE at other sites, such as upper
extremity-, splanchnic- and inferior caval vein thrombosis. Since
breakthrough events are uncommon, complex cases may be over-
represented in the present study, which could limit the generalizability.
Centers did not routinely collect lists of excluded patients, which make
it difficult to assess the risk of selection bias. Finally, no data on long-
term follow-up were available and 5 of the 121 patients were lost to
follow up (4%).
This study showed that in clinical practice many different ap-
proaches in the management of breakthrough events are followed, de-
monstrating the challenges physicians encounter when facing this
clinical problem. Therefore, large management studies are urgently
needed to evaluate the clinical practice and clinical outcome of dif-
ferent strategies in patients with breakthrough events.
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Table 5a
Management at time of breakthrough event and events during 3-month follow-up.
Management breakthrough event Anticoagulant intensity at time of breakthrough event 3 months follow-up
Subtherapeutic N = 21 Therapeutic
N = 76
Supratherapeutic N = 18 Unknown
N = 6⁎
Second breakthrough Bleeding, major/CRNM
Increase intensity 18 61 0 – 5 7
Same intensity 1 12 12 – 1 2
Decreased intensity 0 0 4 – 0 0
Unknown 2 3 2 – 0 0
CRNM: clinically relevant non-major.
Table 5b
Management at time of breakthrough event and events during 3-month follow-up in 6 patients of which the anticoagulant intensity at time of the breakthrough event
was unknown.
Management breakthrough event Anticoagulant intensity at time of breakthrough event 3 months follow-up
Unknown N = 6 Second breakthrough Bleeding, major/CRNM
Therapeutic 2 0 1
Supratherapeutic 3 0 0
Unknown 1 0 0
CRNM: clinically relevant non-major.
Fig. 1. Cumulative incidence of recurrent VTE during 3-month follow-up.
VTE: venous thromboembolism.
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